Conditions: Hepatitis B Virus
Keywords: Severe Hepatic Impairment
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: yes

Brief summary:
The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.

Detailed description:

Arms:
arm 1: Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1. arm 2: Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.

Interventions: intervention 1: TAF
Intervention descriptions: intervention 1: 25 mg tablet administered orally

Protocol document: